Published in BMC Cancer on February 06, 2008
Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PLoS One (2009) 2.82
Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res (2009) 1.96
FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res (2010) 1.95
Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem (2011) 1.94
FoxM1: a master regulator of tumor metastasis. Cancer Res (2011) 1.85
FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res (2010) 1.78
Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat Rev (2009) 1.63
A new target for proteasome inhibitors: FoxM1. Expert Opin Investig Drugs (2010) 1.48
Identification of early molecular markers for breast cancer. Mol Cancer (2011) 1.45
Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer metastasis. J Clin Invest (2014) 1.45
Proteasome inhibitors in cancer therapy. J Cell Commun Signal (2011) 1.38
The 26S proteasome complex: an attractive target for cancer therapy. Biochim Biophys Acta (2011) 1.36
Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells. Genome Biol (2013) 1.31
Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J Cell Biochem (2011) 1.21
Hedgehog signalling in breast cancer. Carcinogenesis (2009) 1.18
A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclin-CDK1. J Biol Chem (2009) 1.17
FoxM1 regulates mammary luminal cell fate. Cell Rep (2012) 1.08
Nucleophosmin interacts with FOXM1 and modulates the level and localization of FOXM1 in human cancer cells. J Biol Chem (2011) 1.06
The critical role of dysregulated FOXM1-PLAUR signaling in human colon cancer progression and metastasis. Clin Cancer Res (2012) 1.05
FoxM1 is a novel target of a natural agent in pancreatic cancer. Pharm Res (2010) 1.01
FoxM1 promotes breast tumorigenesis by activating PDGF-A and forming a positive feedback loop with the PDGF/AKT signaling pathway. Oncotarget (2015) 0.98
Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis. Am J Pathol (2009) 0.96
MicroRNA-194 inhibits the epithelial-mesenchymal transition in gastric cancer cells by targeting FoxM1. Dig Dis Sci (2014) 0.95
Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer (2016) 0.90
FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2. PLoS One (2015) 0.90
Integration of mRNA expression profile, copy number alterations, and microRNA expression levels in breast cancer to improve grade definition. PLoS One (2014) 0.90
Unsupervised feature construction and knowledge extraction from genome-wide assays of breast cancer with denoising autoencoders. Pac Symp Biocomput (2015) 0.88
FOXM1 coming of age: time for translation into clinical benefits? Front Oncol (2012) 0.88
Prognostic discrimination using a 70-gene signature among patients with estrogen receptor-positive breast cancer and an intermediate 21-gene recurrence score. Int J Mol Sci (2013) 0.86
MEK inhibition increases lapatinib sensitivity via modulation of FOXM1. Curr Med Chem (2013) 0.86
p28, a first in class peptide inhibitor of cop1 binding to p53. Br J Cancer (2013) 0.84
3,3'-Diindolylmethane enhances taxotere-induced growth inhibition of breast cancer cells through downregulation of FoxM1. Int J Cancer (2011) 0.82
ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation. Oncogene (2013) 0.82
Overexpression of FOXM1 is associated with metastases of nasopharyngeal carcinoma. Ups J Med Sci (2014) 0.82
The Role of Forkhead Box Protein M1 in Breast Cancer Progression and Resistance to Therapy. Int J Breast Cancer (2016) 0.79
Investigation of FOXM1 as a Potential New Target for Melanoma. PLoS One (2015) 0.79
Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1. Mol Pharmacol (2014) 0.78
Prognostic Value of FOXM1 in Patients with Malignant Solid Tumor: A Meta-Analysis and System Review. Dis Markers (2015) 0.78
Expression of FOXM1 and related proteins in breast cancer molecular subtypes. Int J Exp Pathol (2016) 0.78
Interaction of major genes predisposing to hepatocellular carcinoma with genes encoding signal transduction pathways influences tumor phenotype and prognosis. World J Gastroenterol (2008) 0.77
Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma. J Cancer Res Clin Oncol (2014) 0.77
Down-regulation of FoxM1 by thiostrepton or small interfering RNA inhibits proliferation, transformation ability and angiogenesis, and induces apoptosis of nasopharyngeal carcinoma cells. Int J Clin Exp Pathol (2014) 0.76
Resistance to HER2-targeted therapies: a potential role for FOXM1. Breast Cancer Manag (2015) 0.76
FOXM1 is overexpressed in B-acute lymphoblastic leukemia (B-ALL) and its inhibition sensitizes B-ALL cells to chemotherapeutic drugs. Int J Oncol (2015) 0.75
Integrating Multi-omics Data to Dissect Mechanisms of DNA repair Dysregulation in Breast Cancer. Sci Rep (2016) 0.75
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
[Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe (1987) 7.27
Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev (2000) 5.36
Cell death by mitotic catastrophe: a molecular definition. Oncogene (2004) 4.75
Concern The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist (2003) 3.36
Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res (2005) 3.23
Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res (2001) 3.18
Fox's in development and disease. Trends Genet (2003) 2.80
HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res (2006) 2.74
The winged-helix transcription factor Trident is expressed in cycling cells. Nucleic Acids Res (1997) 2.62
Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res (2006) 2.58
p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol Cell Biol (1986) 2.52
Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst (1998) 2.41
Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res (2007) 2.19
Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene (2006) 2.05
A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J Clin Invest (2006) 2.02
Over-expression of FoxM1 stimulates cyclin B1 expression. FEBS Lett (2001) 1.99
Molecular analysis of a novel winged helix protein, WIN. Expression pattern, DNA binding property, and alternative splicing within the DNA binding domain. J Biol Chem (1997) 1.86
Uncoupling of S phase and mitosis in cardiomyocytes and hepatocytes lacking the winged-helix transcription factor Trident. Curr Biol (1998) 1.72
The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells. J Biol Chem (2006) 1.68
Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res (2006) 1.66
Estrogen and progesterone receptors in the normal female breast. Cancer Res (1991) 1.50
Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet (1987) 1.46
Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity. Oncogene (2005) 1.22
Systematic characterisation of GABRP expression in sporadic breast cancer and normal breast tissue. Int J Cancer (2006) 1.13
Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer. J Pathol (2005) 1.10
Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin Cancer Res (2006) 1.01
Effects of endocrine therapy on steroid-receptor content of breast cancer. Br J Cancer (1982) 0.96
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol (2011) 2.89
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol (2005) 2.83
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol (2009) 2.60
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology (2003) 2.40
ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol (2007) 2.40
WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol (2003) 2.30
CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res (2003) 2.15
Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol (2007) 2.02
Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters. Eur Urol (2008) 2.02
Establishment of a multicolour fluorescence in situ hybridisation-based assay for subtyping of renal cell tumours. Eur Urol (2013) 2.00
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci U S A (2007) 1.97
The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem (2006) 1.96
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol (2004) 1.95
Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol (2007) 1.89
CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol (2002) 1.85
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer (2011) 1.83
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest (2006) 1.78
Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood (2004) 1.76
The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res (2010) 1.75
Numerous IgG4-positive plasma cells are ubiquitous in diverse localised non-specific chronic inflammatory conditions and need to be distinguished from IgG4-related systemic disorders. J Clin Pathol (2011) 1.72
FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol (2007) 1.72
An immunodeficiency disease with RAG mutations and granulomas. N Engl J Med (2008) 1.71
Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One (2012) 1.67
Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res (2006) 1.66
Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res (2011) 1.65
The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility. J Cell Biol (2008) 1.63
The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression. Eur Urol (2009) 1.62
The death-domain fold of the ASC PYRIN domain, presenting a basis for PYRIN/PYRIN recognition. J Mol Biol (2003) 1.61
Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol (2010) 1.60
Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol (2005) 1.60
Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol (2005) 1.58
HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence. Clin Gastroenterol Hepatol (2003) 1.55
Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J Urol (2006) 1.54
GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol (2009) 1.54
Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation. Transplantation (2012) 1.52
Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol (2005) 1.51
Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. Breast Cancer Res Treat (2007) 1.49
The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol (2009) 1.49
miRNA-26b Overexpression in Ulcerative Colitis-associated Carcinogenesis. Inflamm Bowel Dis (2015) 1.47
Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology (2009) 1.47
MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer (2011) 1.47
On a dark-field signal generated by micrometer-sized calcifications in phase-contrast mammography. Phys Med Biol (2013) 1.47
Targeting the Wnt pathway in cancer: the emerging role of Dickkopf-3. Biochim Biophys Acta (2011) 1.47
Prognostic value of perinodal lymphovascular invasion following radical cystectomy for lymph node-positive urothelial carcinoma. Eur Urol (2012) 1.46
Expression of the glioma-associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavourable overall survival. BMC Cancer (2009) 1.43
Calcifying fibrous tumor of the stomach: clinicopathologic and molecular study of seven cases with literature review and reappraisal of histogenesis. Am J Surg Pathol (2010) 1.43
Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One (2010) 1.41
Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res (2008) 1.40
Prognostic relevance of AGR2 expression in breast cancer. Clin Cancer Res (2006) 1.40
KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res (2011) 1.38
Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients. J Pathol (2013) 1.38
MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia (2010) 1.37
Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer (2009) 1.37
High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J Invest Dermatol (2006) 1.37
Quality assured health care in certified breast centers and improvement of the prognosis of breast cancer patients. Onkologie (2011) 1.36
Peripheral nerve sheath tumors of the gastrointestinal tract: a multicenter study of 58 patients including NF1-associated gastric schwannoma and unusual morphologic variants. Virchows Arch (2010) 1.36
Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest (2004) 1.35
Serological pattern "anti-HBc alone": characterization of 552 individuals and clinical significance. World J Gastroenterol (2006) 1.34
Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: a systematic expression analysis. BMC Cancer (2008) 1.34
Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer (2002) 1.34
Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. J Cell Mol Med (2008) 1.33
Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Clin Cancer Res (2007) 1.33
Different types of microsatellite instability in ovarian carcinoma. Int J Cancer (2004) 1.30
PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation. Oncogene (2005) 1.30
Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours. Breast Cancer Res (2008) 1.29
The plasmacytoid carcinoma of the bladder--rare variant of aggressive urothelial carcinoma. Int J Cancer (2010) 1.29
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis (2013) 1.28
Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis. Carcinogenesis (2008) 1.27
Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer (2009) 1.26
Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage. J Pathol (2004) 1.26
Signaling by IL-31 and functional consequences. Eur J Cell Biol (2011) 1.25
Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology (2010) 1.25
Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer (2008) 1.23
Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Clin Cancer Res (2005) 1.23
Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res (2005) 1.22
The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Res (2008) 1.21